Mark Lackner Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity

ZNTL Quotes by TradingView

Mark Lackner is Chief Scientific Officer of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 191,317 shares of ZNTL, which is worth approximately $440,029. The most recent transaction as insider was on Jan 02, 2025, when has been sold 4,411 shares (Common Stock) at a price of $3.12 per share, resulting in proceeds of $13,762. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 191K
2.25% 3M change
239.74% 12M change
Total Value Held $440,029

Mark Lackner Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 02 2025
SELL
Open market or private sale
$13,762 $3.12 p/Share
4,411 Reduced 2.25%
191,317 Common Stock
Feb 02 2024
SELL
Open market or private sale
$18,290 $11.54 p/Share
1,585 Reduced 0.8%
195,728 Common Stock
Feb 01 2024
BUY
Grant, award, or other acquisition
-
141,000 Added 41.68%
197,313 Common Stock
Jan 02 2024
BUY
Grant, award, or other acquisition
-
40,000 Added 41.53%
56,313 Common Stock

Also insider at

IDYA
IDEAYA Biosciences, Inc. Healthcare
SVP, Head of Biology
ML

Mark Lackner

Chief Scientific Officer
South San Francisco, CA

Track Institutional and Insider Activities on ZNTL

Follow Zentalis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ZNTL shares.

Notify only if

Insider Trading

Get notified when an Zentalis Pharmaceuticals, Inc. insider buys or sells ZNTL shares.

Notify only if

News

Receive news related to Zentalis Pharmaceuticals, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ZNTL